Drug discovery and development is a costly, time-consuming process with a high risk of failure. One approach to save time and mitigate risk is to increase the use of cell-based assays as an alternative to biochemical assays. Cell-based assays (2D and 3D) enable interrogation of a target in a physiological context and have the potential to be used in all phases from target discovery up to preclinical development.